CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
ELEQUILother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05328973
NCT05328973Phase 2Completed
CompareCT.gov

Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial

M.D. Anderson Cancer Center·interventional·Posted Apr 14, 2022·Updated Dec 2, 2024

In Brief

A Phase 2 clinical trial evaluating ELEQUIL for Cancer Pain. Completed, enrolled 70 participants across 1 site.

Detailed Summary

This is a prospective, controlled, randomized trial. Primary objective is to compare the time to readiness for discharge (minutes) from Post-Anesthesia Care Unit (PACU) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo. 70 Eligible subjects will be identified from within the patient population of the study site. There will be no advertisements for study subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 14, 2022
Enrollment StartMay 18, 2022
Primary CompletionJan 16, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.2 years ago

Interventions

ELEQUILother

patch placed on skin